Last reviewed · How we verify
MenABCYW conjugate vaccine
MenABCYW conjugate vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development. Also known as: PENBRAYATM.
At a glance
| Generic name | MenABCYW conjugate vaccine |
|---|---|
| Also known as | PENBRAYATM |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenABCYW conjugate vaccine CI brief — competitive landscape report
- MenABCYW conjugate vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about MenABCYW conjugate vaccine
What is MenABCYW conjugate vaccine?
MenABCYW conjugate vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes MenABCYW conjugate vaccine?
MenABCYW conjugate vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is MenABCYW conjugate vaccine also known as anything else?
MenABCYW conjugate vaccine is also known as PENBRAYATM.
What development phase is MenABCYW conjugate vaccine in?
MenABCYW conjugate vaccine is in Phase 1.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: PENBRAYATM
- Compare: MenABCYW conjugate vaccine vs similar drugs
- Pricing: MenABCYW conjugate vaccine cost, discount & access